Germany
Japan
United Kingdom
China
AAV6 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 50 ul
AAV Control Particles
View as table Download
AAV7 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 2 x 50 ul
AAV7 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 50 ul
AAV1 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 2 x 50 ul
AAV1 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 50 ul
AAVrh.10 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 2 x 50 ul
AAVrh.10 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 50 ul
AAV5 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 50 ul
AAV-PHP.eB with CMV promoter-driven expression of GFP, >10^13 GC/mL, 2 x 50 ul
AAV2 control particles, shRNA scramble, expressing GFP and puro, >10^13 GC/mL, 2 x 50 ul
AAV2 control particles, shRNA scramble, expressing GFP and puro, >10^13 GC/mL, 50 ul
AAV9 control particles, shRNA scramble, expressing GFP and puro, >10^13 GC/mL, 2 x 50 ul
AAV9 control particles, shRNA scramble, expressing GFP and puro, >10^13 GC/mL, 50 ul
AAV5 control particles, shRNA scramble, expressing GFP and puro, >10^13 GC/mL, 2 x 50 ul
AAV5 control particles, shRNA scramble, expressing GFP and puro, >10^13 GC/mL, 50 ul